YOU MATTER.
Publications
0
%
5-Year Survival Rate Percentage increase from 2007 through 2013
0
Estimated new cases in the US, this year
0
Estimated Deaths in the US, this year
0
People are living with kidney and renal pelvis cancer, according to NCI SEER data from 2014
Evaluate your treatment options and make decisions
From the Pressroom
News from Kidney Cancer Association This feed has been created by Kidney Cancer Association
-
A Novel Approach: TKI/I-O Combinations in RCC
on December 11, 2018 at 6:07 pm
Insights From: Brian Rini,MD, Cleveland Clinic Main Campus; David F. McDermott, MD, Harvard Cancer Center12/11/2018 […]
-
Clinical Trials in Renal Cell Carcinoma
on December 11, 2018 at 6:03 pm
Dr. Brian Rini and Dr. David F. McDermott discuss two different clinical trials for #KidneyCancer patients.12/11/2018 […]
-
An overview of renal cell carcinoma
on December 10, 2018 at 3:47 pm
RCC is the seventh leading cause of cancer deaths in the U.S. Check out this article for an overview of the condition.12/10/2018 […]
YOU MATTER.
WE CARE.
YOU ARE NOT ALONE.
Kidney Cancer Association
The Kidney Cancer Association (KCA) is a charitable organization made up of patients, family members, physicians, researchers, and other health professionals globally. It is the world’s first international charity dedicated specifically to the eradication of death and suffering from renal cancers.
Archived News
Advocates, patients, providers, and other experts share perspectives on the challenges that prevent equitable opportunities and outcomes for people with cancer.
nccn.org
Other Clinical Trials in Renal Cell Carcinoma
A number of other clinical trials are outlined in the setting of renal cell carcinoma, whether they be with targeted/immunotherapy combinations, immunotherapy/immunotherapy combinations, or immunotherapy monotherapy.
onclive.com
Renal Cell Carcinoma
Cancer Therapy Advisor provides oncologists and oncology specialists with the latest information to correctly diagnose the latest cancer conditions, recommend procedures and guides. Visit often for updates and new information.
cancertherapyadvisor.com
17 hours ago
The KCA was proud be a part of NCCN’s Patient Advocacy Summit yesterday. The main focus was advocating for equity in cancer care. The summit included case studies, presentations, and panel discussions, all highlighting... https://t.co/cAIy8XxS7X
The KCA was proud be a part of NCCN’s Patient Advocacy Summit yesterday. The main focus was advocating for equity in cancer care. The summit included case studies, presentations, and panel discussions, all highlighting... https://t.co/cAIy8XxS7X
The KCA was proud be a part of NCCN’s Patient Advocacy Summit yesterday. The main focus was advocating for equity in cancer care. The summit included case studies, presentations, and panel discussions, all highlighting... https://t.co/cAIy8XxS7X
— Kidney Cancer (@KidneyCancer) December 11, 2018
17 hours ago
Proud to be a part of this summit yesterday! https://t.co/NrqX0av6ko
Proud to be a part of this summit yesterday! https://t.co/NrqX0av6ko
"Cancer care practices are improving every day, but we have to work together to make sure those advancements are accessible to everyone." Read about today's NCCN Patient Advocacy Summit on #Equity in #CancerCare >> https://t.co/yjaOctA2wh #NCCNPatients pic.twitter.com/cOtCXyby6l
— National Comprehensive Cancer Network (NCCN) (@NCCNnews) December 10, 2018
National Comprehensive Cancer Network (NCCN)
@NCCNnews
"Cancer care practices are improving every day, but we have to work together to make sure those advancements are accessible to everyone." Read about today's NCCN Patient Advocacy Summit on #Equity in #CancerCare >> https://t.co/yjaOctA2wh #NCCNPatients https://t.co/cOtCXyby6l
"Cancer care practices are improving every day, but we have to work together to make sure those advancements are accessible to everyone." Read about today's NCCN Patient Advocacy Summit on #Equity in #CancerCare >> https://t.co/yjaOctA2wh #NCCNPatients https://t.co/cOtCXyby6l
17 hours ago
Dr. Brian Rini and Dr. David F. McDermott discuss two different clinical trials for #KidneyCancer patients. https://t.co/hyRKLeNGOt
Dr. Brian Rini and Dr. David F. McDermott discuss two different clinical trials for #KidneyCancer patients. https://t.co/hyRKLeNGOt
Dr. Brian Rini and Dr. David F. McDermott discuss two different clinical trials for #KidneyCancer patients. https://t.co/hyRKLeNGOt
— Kidney Cancer (@KidneyCancer) December 11, 2018